MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase

Cancer Research

Volumn 71, Issue 6, 2011, Pages 2286-2297

  Cao, Zhongwei ^a   Fan Minogue, Hua ^a   Bellovin, David I ^a   Yevtodiyenko, Aleksey ^a   Arzeno, Julia ^a   Yang, Qiwei ^a   Gambhir, Sanjiv Sam ^a   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYCLIN DEPENDENT KINASE 4; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; MYC PROTEIN; NUCLEOLIN; RAC PROTEIN; SERINE; THREONINE; TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TRANSACTIVATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOBLOTTING; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICE; MICE, SCID; MICE, TRANSGENIC; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; PYRROLES; RAC GTP-BINDING PROTEINS; SERINE; THREONINE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952764351     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3367     Document Type: Article

References (52)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87. (Pubitemid 44286000)
2. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006;43:S45-53.
3. Riehle KJ, Campbell JS, McMahan RS, Johnson MM, Beyer RP, Bammler TK, et al. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med 2008;205:91-103. (Pubitemid 351185718)
4. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3:573-88. (Pubitemid 37168599)
5. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004;36: 1306-11. (Pubitemid 39577940)
6. Thorgeirsson SS, Factor VM, Snyderwine EG. Transgenic mouse models in carcinogenesis research and testing. Toxicol Lett 2000;112-113:553-5. (Pubitemid 30138170)
7. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al.MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7. (Pubitemid 39472236)
8. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45. (Pubitemid 41081267)
9. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009;69:2775-82.
10. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999;18:717-26. (Pubitemid 29057256)
11. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003;278:51606-12. (Pubitemid 38020405)
12. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-14.
13. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-18. (Pubitemid 38584820)
14. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993;5:56-61. (Pubitemid 23261519)
15. Smith-Sorensen B, Hijmans EM, Beijersbergen RL, Bernards R. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins. J Biol Chem 1996;271:5513-8. (Pubitemid 26083883)
16. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42. (Pubitemid 41766782)
17. Shibata MA, Ito Y, Morimoto J, Otsuki Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 2004;25:1887-98. (Pubitemid 39405908)
18. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 2000;6:2044-52. (Pubitemid 30305104)
19. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
20. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19. (Pubitemid 34460459)
21. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M, Aizawa R. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996;87:798-804. (Pubitemid 26335806)
22. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999;117:838-47. (Pubitemid 29468226)
23. Denoyelle C, Albanese P, Uzan G, Hong L, Vannier JP, Soria J, et al. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 2003;15:327-38. (Pubitemid 36071677)
24. He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 1997;127:668-74. (Pubitemid 27200738)
25. Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, et al. Inhibition of HMGCoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 2007;110:2674-84. (Pubitemid 47523192)
26. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist 2006;11:306-15.
27. Jackson SM, Ericsson J, Edwards PA. Signaling molecules derived from the cholesterol biosynthetic pathway. Subcell Biochem 1997;28:1-21.
28. Chiariello M, Marinissen MJ, Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol 2001;3:580-6. (Pubitemid 32536855)
29. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001;108:981-90. (Pubitemid 32946072)
30. Paulmurugan R, Gambhir SS. Monitoring protein-protein interactions using split synthetic Renilla luciferase protein-fragment-assisted complementation. Anal Chem 2003;75:1584-9. (Pubitemid 36512595)
31. Fan-Minogue H, Cao Z, Paulmurugan R, Chan CT, Massoud TF, Felsher DW, et al. Noninvasive molecular imaging of c-Myc activation in living mice. Proc Natl Acad Sci U S A 107:15892-7.
32. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-66. (Pubitemid 29359019)
33. Black AE, Sinz MW, Hayes RN, Woolf TF. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy- 3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 1998;26:755-63. (Pubitemid 28376434)
34. Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prev Res (Phila) 2009;2:161-7.
35. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18:853-6.
36. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61. (Pubitemid 351348146)
37. Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 1994;14:5510-22. (Pubitemid 24235980)
38. Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139-48. (Pubitemid 32737327)
39. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci U S A 1991; 88:3628-32. (Pubitemid 21916676)
40. Henriksson M, Bakardjiev A, Klein G, Luscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 1993;8:3199-209. (Pubitemid 23342616)
41. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 2004;320:165-9. (Pubitemid 38781797)
42. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.
43. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45. (Pubitemid 34157379)
44. Tilkin-Mariamé AF, Cormary C, Ferro N, Sarrabayrouse G, Lajoie- Mazenc I, Faye JC, et al. Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression. FASEB J 2005;19:1513-5. (Pubitemid 41279015)
45. Mueck AO, Seeger H, Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 2003;10:332-6. (Pubitemid 36870505)
46. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003;9:10-9. (Pubitemid 36109711)
47. Agarwal B, Halmos B, Feoktistov AS, Protiva P, Ramey WG, Chen M, et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 2002;23:521-8. (Pubitemid 34257633)
48. ten Klooster JP, Leeuwen I, Scheres N, Anthony EC, Hordijk PL. Rac1- induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J 2007;26:336-45.
49. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
50. Graf H, J€ungst C, Straub G, Dogan S, Hoffmann RT, Jakobs T, et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008;78:34-8.
51. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-91. (Pubitemid 32385829)
52. Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, Eckel F, et al. Treatment of HCC with pravastatin, octreotide, or gemcitabine - a critical evaluation. Hepatogastroenterology 2004; 51:1099-103. (Pubitemid 38822478)